NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00276276,Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00276276,,COMPLETED,The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them. The study will compare how long patients live when they are given therapy to make them feel better (active symptom control) to the length of time patients live when they are also receiving oral HYCAMTIN.,NO,"Lung Cancer, Small Cell",DRUG: topotecan,Overall survival,"Time to response, response rate, time to disease progression",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,141,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,104864/478,2000-11,,,2006-01-13,,2013-04-15,"GSK Investigational Site, Pleven, Bulgaria|GSK Investigational Site, Plovdiv, 4000, Bulgaria|GSK Investigational Site, Varna, 9010, Bulgaria|GSK Investigational Site, Budapest, 1115, Hungary|GSK Investigational Site, Budapest, 1145, Hungary|GSK Investigational Site, Budapest, 1529, Hungary|GSK Investigational Site, Csorna, 9300, Hungary|GSK Investigational Site, Hungary, 8900, Hungary|GSK Investigational Site, Miskolc, 3529, Hungary|GSK Investigational Site, Törökbálint, 2045, Hungary|GSK Investigational Site, Breda, 4819 EV, Netherlands|GSK Investigational Site, Moscow, 115 478, Russian Federation|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Lvov, 79031, Ukraine|GSK Investigational Site, Chelmsford, Essex, CM1 7ET, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, G21 3UW, United Kingdom|GSK Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom",
